Business
ProtoKinetix’ AAGP™ has been Published in the Journal of Tissue Engineering and Regenerative Medicine
ProtoKinetix’ AAGP™ has been Published in the Journal of Tissue Engineering and Regenerative Medicine.
About this update from Protokinetix, Inc.
[{"type":"text","content":"\n \n ProtoKinetix, Incorporated (OTCQB:PKTX) \n (the \"Company\" or \"ProtoKinetix\") (www.protokinetix.com) \n is pleased to announce that a paper submitted by Dr. Kevin Gregory-Evans \n on ProtoKinetix’ AAGP™ has been published in the Journal of Tissue \n Engineering and Regenerative Medicine and is available online at:\n \n \n Anti-ageing \n glycoprotein promotes long-term survival of transplanted neurosensory \n precursor cells\n \n \n AAGP™, an antifreeze glycopeptide, has been demonstrated to \n significantly improve the viable yield of stem cells transplanted in \n retinal tissue at the University of British Columbia under the guidance \n of Dr. Kevin Gregory-Evans.\n \n \n ProtoKinetix has entered into a research agreement with the University \n of British Columbia to research neuronal cell transplantation as an \n extension of the studies recently published by Dr. Gregory-Evans in the \n Journal of Tissue Engineering and Regenerative Medicine.\n \n \n Regarding the new studies, IN VIVO STUDIES TO DETERMINE THE POTENTIAL OF \n ANTI-AGING GLYCOPROTEIN (AAGP™) IN ENHANCING THE LONGTERM SURVIVAL OF \n NEURAL STEM CELLS, Dr. Gregory-Evans explains: “My research team at \n the University of British Columbia is very excited to move on to the \n next stage of our studies with ProtoKinetix’ compound AAGP™. We have \n shown that it is useful, in a simple model system, at promoting stem \n cell survival in tissue transplantation experiments. The next stage is \n now to move into animal model systems. This is for three reasons, first \n because it will give us a better quantitative understanding of AAGPs™ \n effectiveness, that is not only will it show us if AAGP™ works but also \n how well in might work in humans. Second, it will show us if there are \n any toxicity concerns in our target tissue (the central nervous system) \n and third as a regulatory requirement before undertaking human studies. \n Our major interest is blinding eye disease and stroke. We will study \n AAGP™ in models of both these common central nervous system ailments \n with the hope that, all going well, we can move on to early clinical \n studies in human sufferers within the next five years. Tissue \n transplantation promises to revolutionize the medicine of tomorrow and \n we think AAGP™ w...